Genetic and molecular analysis of solid tumors with immunotherapy associated hyperprogressive disease


D. Trotier1, J. McGrath2, J. Xiu2, P. Grover3, C. Park3, T. Wise-Draper3

  • Immune checkpoint inhibitor use is common in oncology care
  • A rare paradoxical rapid progression in tumor growth after initiation of immunotherapy (Figure 1) has been described and termed Hyperprogressive disease (HPD)
  • Frequency of HPD has been reported from 6% to 29%, with highest frequency in HNSCC and NSCLC
  • EGFR mutations and MDM2/4 amplifications have been implicated in HPD, but underlying molecular mechanism remains unclear necessitating further study

Download Publication